drugset
drugset / Trial / NCT06229366

[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer

NCT06229366 ↗

Phase 1 Active not recruiting 142 enrolled Eli Lilly and Company
Non-randomizedParallel-groupOpen-labelTreatment

Summary

ACCEL is a multicenter, open label phase Ia/Ib/II study of \[Ac-225\]-PSMA-62 in participants with prostate-specific membrane antigen (PSMA)-positive prostate cancer.

Timeline

Start
2024-04-03
Primary completion
2027-09
Completion
2032-12

Drugs

EvaluationDrugModalityDoseRoute
Subject [Ac-225]-PSMA-62 Unknown — Intravenous

Indications

prostate carcinoma